Compositions and methods for diagnosing and treating kidney disorders in a canine

• US 9,476,868 B2
• Filed: 12/23/2010
• Issued: 10/25/2016
• Est. Priority Date: 12/23/2009
• Status: Active Grant

• Current Assignee: Hill's Pet Nutrition Incorporated (Colgate-Palmolive Company)
• Original Assignee: Hill's Pet Nutrition Incorporated (Colgate-Palmolive Company)
• Inventors: Al-Murrani, Samer, Malladi, Sukhaswami, Gao, Xiangming
• Primary Examiner(s): Hibbert, Catherine S
• Application Number:
  US13/519,048
• Publication Number:
  US 20120283129A1
• Time in Patent Office: 2,133 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2800/347 Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
• CPC Class Codes: G01N 33/50 Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q

Abstract

The present invention provides methods for: diagnosing of, devising and monitoring a treatment plan for, and monitoring the status of a kidney disorder characterized by an abnormal loss of renal function, renal failure, reduced glomerular filtration rate or glomerulonephritis, in a canine, wherein the kidney disorder is detectable by utilizing at least one relevant biomarker isolated and measured from a biological test sample taken from such canine. The invention additionally relates to compositions, reagents and kits for carrying out the specified methods.

Claims

1. A method of treating, ameliorating, or delaying the progression of a kidney disorder in a canine, comprising the steps of:

(a) diagnosing the kidney disorder by measuring the level of expression of at least one biomarker in a biological sample from the canine, wherein the at least one biomarker is selected from secreted frizzle-related protein-2 (SFRP2);

matrilin-2 (Matn2);

lumican (LUM);

retinol binding protein 4 (rbp4);

transferrin (TF);

Apo-C-1 (ApoC1); and

inhibin beta A (INHBA), and wherein the test sample is a sample of solid kidney tissue or a bodily fluid;

(b) identifying the canine as having a kidney disorder wherein differences in expression of one or more biomarkers in the sample relative to a control value for expression in a sample from a normal animal indicates the existence of a kidney disorder, and wherein the differences in expression are determined with a custom array consisting of two or more probes specific to the biomarkers selected from matrilin-2 (Matn2);

lumican (LUM);

retinol binding protein 4 (rbp4);

transferrin (TF);

Apo-C-1 (ApoC1); and

inhibin beta A (INHBA); and

(c) treating, ameliorating, or delaying the progression of the kidney disorder in the canine identified in step (b);

wherein the kidney disorder is indicated by a significant difference in expression of one or more biomarkers relative to control expression values wherein a significant difference in the case of increased expression is an increase of at least twofold and in the case of decreased expression is a decrease of at least 50% and wherein one or more biomarkers is selected from;

matrilin-2 (Matn2);

lumican (LUM);

retinol binding protein 4 (rbp4);

transferrin (TF);

Apo-C-1 (ApoC1); and

inhibin beta A (INHBA), and

wherein the canine has normal renal function, wherein normal renal function is determined by one or more of;

glomular filtration rate, urine protein level, blood creatinine level, urine creatinine level, creatinine clearance and blood urea nitrogen.

2. The method of claim 1, wherein the differential expression of step (b) is determined with a panel of one or more antibodies that specifically bind to the at least one biomarker.

3. The method of claim 1, wherein the differential expression of step (b) is determined by immunoassay to detect the at least one biomarker.

4. The method of claim 3, wherein the immunoassay is selected from the group consisting of a competitive binding assay, a non-competitive binding assay, a radioimmunoassay, an enzyme linked immunosorbent assay (ELISA), a sandwich assay, a precipitin reaction, a gel diffusion immunodiffusion assay, an agglutination assay, a fluorescent immunoassay, chemiluminescence immunoassay, immunoPCR immunoassay, a protein A or protein G immunoassay, Northern blot analysis, Western blot analysis, bead-based multiplexed assay and an immunoelectrophoresis assay.

5. The method of claim 1, further comprising use of one or more conventional diagnostic measurement selected from the group consisting of:

determining levels of albumin, determining levels of serum cystatin C, determining levels of blood creatinine, determining levels of urinary creatinine, determining levels of creatinine clearance, determining levels of urinary protein, determining levels of blood urea nitrogen and determining glomerular filtration rate.